The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice

Molecular Endocrinology

Volumn 26, Issue 2, 2012, Pages 341-348

  Onal, Melda ^a   Galli, Carlo ^a   Fu, Qiang ^a   Xiong, Jinhu ^a   Weinstein, Robert S ^a   Manolagas, Stavros C ^a   O'Brien, Charles A ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE; CALCIUM DEFICIENCY; CALCIUM INTAKE; CANCELLOUS BONE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENOTYPE; HYPERPARATHYROIDISM; KNOCKOUT MOUSE; LACTATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE;

ANIMALS; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; CALCIUM; ENHANCER ELEMENTS, GENETIC; FEMALE; FEMUR; GENE EXPRESSION REGULATION; HYPERPARATHYROIDISM; LACTATION; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; RANK LIGAND; SPINE;

MUS;

EID: 84856241068     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1149     Document Type: Article

References (31)

1. Parfitt AM 1987 Bone and plasma calcium homeostasis. Bone 8(Suppl 1):S1-S8
2. Kovacs CS 2005 Calcium and bone metabolism during pregnancy and lactation. J Mammary Gland Biol Neoplasia 10:105-118
3. Robling AG, Castillo AB, Turner CH 2006 Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng 8:455-498.
4. Schindeler A, McDonald MM, Bokko P, Little DG 2008 Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol 19:459-466.
5. Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
6. Manolagas SC 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137 (Review)
7. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
9. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC 1999 STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-KB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D-3 or parathyroid hormone. J Biol Chem 274:19301-19308.
10. Lee SK, Lorenzo JA 1999 Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast- like cell formation. Endocrinology 140:3552-3561.
11. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA 2011 Matrix-embedded cells control osteoclast formation. Nat Med 17:1235-1241.
12. Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G 2006 Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 116:3150-3159.
13. Fu Q, Jilka RL, Manolagas SC, O'Brien CA 2002 Parathyroid hormone stimulates receptor activator of NFKB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875
14. Fu Q, Manolagas SC, O'Brien CA 2006 Parathyroid hormone controls receptor activator of NF-KB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 26:6453-6468.
15. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA 2008 Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-KB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 149:146-153.
16. Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW 2006 Activation of receptor activator of NF-KB ligand gene expression by 1,25- dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 26:6469-6486.
17. Brown EM, Juppner H 2006 Parathyroid hormone: synthesis, secretion, and action. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 90-99.
18. Wysolmerski JJ 2010 Interactions between breast, bone, and brain regulate mineral and skeletal metabolism during lactation. Ann NY Acad Sci 1192:161-169.
19. Ardeshirpour L, Dann P, Adams DJ, Nelson T, VanHouten J, Horowitz MC, Wysolmerski JJ 2007 Weaning triggers a decrease in receptor activator of nuclear factor-KB ligand expression, widespread osteoclast apoptosis, and rapid recovery of bone mass after lactation in mice. Endocrinology 148:3875-3886.
20. O'Brien CA 2010 Control of RANKL gene expression. Bone 46: 911-919.
21. Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM, Takahashi N 2007 Osteoprotegerin reduces the serum level of receptor activator of NF-KB ligand derived from osteoblasts. J Immunol 178:192-200.
22. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
23. VanHouten JN, Wysolmerski JJ 2003 Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. Endocrinology 144:5521-5529.
24. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
25. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC 2010 The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 24: 323-334.
26. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S 2007 Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell 130:811-823
27. Miao D, He B, Lanske B, Bai XY, Tong XK, Hendy GN, Goltzman D, Karaplis AC 2004 Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology 145:2046-2053.
28. Kirby BJ, Ardeshirpour L, Woodrow JP, Wysolmerski JJ, Sims NA, Karaplis AC, Kovacs CS 2011 Skeletal recovery after weaning does not require PTHrP. J Bone Miner Res 26:1242-1251.
29. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
30. O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC 2005 IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 289:E784-E793
31. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 25:402-408